Tagraxofusp 产品活性：Tagraxofusp (SL-401) 是一种有效的 IL-3 受体抑制剂，可抑制多发性骨髓瘤 (MM) 骨髓 (BM) 微环境中浆细胞样树突状细胞 (pDCs) 的生长。Tagraxofusp 与 Bortezomib (HY-10227)、Pomalidomide (HY-10984) 有协同抑制多发性骨髓瘤的作用。 产品来源： https://www.medchemexpress.cn/tagraxofusp.html 研究领域：Immunology/Inflammation 作用靶点：Interleukin Related In Vitro: Tagraxofusp (0-1367 pM; 72 h) inhibits pDCs viability, as well as pDC-induced proliferation of MM cells. Tagraxofusp (0-136.7 pM; 2-3 weeks) inhibits osteoclast formation and bone resorption, as well as stabilizes osteoblast formation. Tagraxofusp (0-13.67 nM; 48 h) targets tumor-initiating stem-like cells in MM. In Vivo: Tagraxofusp (12-50 μg/kg; i.v.; 5 times per week for 3 weeks) blocks pDC-induced tumor growth and prolongs SCID-hu mice survival in subcutaneous INA-6 MM xenograft model. Tagraxofusp (16 μg/kg; i.v.; 5 times per week for 1 weeks) enhances the anti-MM activity of 2.5 mg/kg Pomalidomide in CB-17 mice of subcutaneous MM xenograft model. 相关产品：Resatorvid | Disulfiram | Polyinosinic-polycytidylic acid | Raleukin | Deucravacitinib | Dupilumab | Tocilizumab | Apilimod | Oxidopamine hydrobromide | LMT-28 | Theophylline | Secukinumab | Clofazimine | Sodium metatungstate | Benzbromarone | SC144 | Hydrocortisone hemisuccinate | LY3509754 | ODN 2216 | Muscone | Diacerein | JTE-607 | Ixekizumab | APY0201 | Risankizumab | Lysophosphatidylcholines | Ustekinumab | Fibrinogen (Bovine) 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。